Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Overall etiology of ventilator-associated pneumonia and the distributions by group

From: Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial

PathogensNumber (%)Colistin + levofloxacin group (%)Meropenem + levofloxacin group (%)Risk ratio (95% CI)p value
Total212108104  
Gram-negative bacilli174 (82.1)89 (82.4)85 (81.7)  
Acinetobacter baumannii34 (16.0)16 (14.8)18 (17.3)0.83 (0.39, 1.74)0.621
Pseudomonas aeruginosa34 (16.0)19 (17.6)15 (14.4)1.27 (0.60, 2.69)0.530
Klebsiella pneumoniae29 (13.6)14 (13)15 (14.4)0.88 (0.40, 1.96)0.757
Escherichia coli20 (9.4)12 (11.1)8 (7.7)1.50 (0.58, 4.01)0.395
Enterobacter aerogenes13 (6.1)6 (5.6)7 (6.7)0.82 (0.25, 2.60)0.721
Enterobacter cloacae10 (4.7)5 (4.6)5 (4.8)0.96 (0.25, 3.68)0.951
Proteus mirabilis7 (3.3)2 (1.9)5 (4.8)2.76 (0.52, 14.51)0.213
Klebsiella oxytoca6 (2.8)4 (3.7)2 (1.9)0.53 (0.10, 2.94)0.458
Serratia spp.5 (2.3)4 (3.7)1 (0.9)0.26 (0.03, 2.37)0.201
Haemophilus influenzae4 (1.8)1 (0.9)3 (2.9)3.28 (0.34, 31.96)0.281
Citrobacter freundii4 (1.8)1 (0.9)3 (2.9)  
Citrobacter koseri3 (1.4)2 (1.9)1 (0.9)0.53 (0.05, 5.94)0.602
Stenotrophomonas maltophilia3 (1.4)2 (1.9)1 (0.9)0.53 (0.05, 5.94)0.602
Achromobacter xylosoxidans2 (1.0)1 (0.9)1 (0.9)1.07 (0.07, 17.35)0.961
Gram-positive aerobes38 (17.9)19 (17.6)19 (18.3)  
Staphylococcus aureus26 (12.2)14 (13)12 (11.5)1.14 (0.50, 2.66)0.751
Enterococcus spp.8 (3.8)3 (2.8)5 (4.8)1.82 (0.43, 7.81)0.413
Streptococcus pneumoniae3 (1.4)1 (0.9)2 (1.9)2.16 (0.19, 24.20)0.521
Streptococcus sp.1 (0.004)1 (0.9)0 (0.0)0.325
Total212 (100)a108 (100)104 (100)  
  1. a55 cases of VAP were polymicrobial. CI confidence interval